4/15/2016
The FDA has recently approved a revised dosing schedule for Pfizer’s Serogroup B Meningococcal Vaccine. Please see the most recent prescribing information which includes the updated dosing schedule.
The updated dosing schedule provides healthcare providers additional options in determining which dosing schedule is most appropriate for individual patients to help prevent invasive disease caused by Neisseria meningitidis serogroup B.
Any specific questions regarding the updated label, please reach out to Pfizer Vaccine’s Medical Information at 1-800-438-1985.